10-(3,7,11-trimethyldodecyl)-4,6,8-trihydroxy-5-methyl-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one | 870702-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 10-(3,7,11-trimethyldodecyl)-4,6,8-trihydroxy-5-methyl-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one
• 英文别名: 1,3,10-Trihydroxy-11-methyl-5-(3,7,11-trimethyldodecyl)benzo[b][1,4]benzodiazepin-6-one
• CAS: 870702-39-9
• 化学式: C₂₉H₄₂N₂O₄
• 分子量: 482.663
• InChiKey: HGWYMSHDNNGAIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  84.2
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  10-farnesyl-4,6,8-trihydroxy-5-methyl-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one 在 platinum(IV) oxide 氢气 作用下， 以 甲醇 为溶剂， 生成 10-(3,7,11-trimethyldodecyl)-4,6,8-trihydroxy-5-methyl-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one
  参考文献：
  名称：

  TUMOR-TARGETING EVALUATION METHODOLOGY AND COMPOUNDS RELATED THERETO

  摘要：

  该发明涉及一种评估候选分子化疗潜力的方法。在评估候选分子时，将测试候选分子抑制癌细胞体外生长的能力；结合由癌细胞产生的细胞受体，其中所述受体，如外周苯二氮卓受体，由所述癌细胞产生的数量比正常细胞多；并抑制MAPK通路中至少一个蛋白质成员的活性。该发明还涉及二苯二氮卓酮类似物及其衍生物。

  公开号：

  US20090062255A1

文献信息

• Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
  申请人：McAlpine B. James

  公开号：US20060079509A1

  公开（公告）日：2006-04-13

  The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, to pharmaceutical compositions comprising them and to methods of treating neoplastic conditions.

  本发明涉及由式 I 表示的具有生物活性的二苯并二氮杂卓类似物、生产它们的方法、包含它们的药物组合物以及治疗肿瘤疾病的方法。
• DIBENZODIAZEPINONE ANALOGUES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS
  申请人：Ecopia Biosciences Inc.

  公开号：EP1809612A1

  公开（公告）日：2007-07-25
• EP1809612A4
  申请人：——

  公开号：EP1809612A4

  公开（公告）日：2009-05-27
• Dibenzodiazepinone Analogues, Processes for Their Production and Their Use as Pharmaceuticals
  申请人：McAlpine James B.

  公开号：US20090029972A1

  公开（公告）日：2009-01-29

  The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, and their use in the preparation of medicaments for the treatment of neoplastic conditions
• METHODS FOR TREATING RAS DRIVEN CANCER IN A SUBJECT
  申请人：GOURDEAU Henriette

  公开号：US20090170837A1

  公开（公告）日：2009-07-02

  The invention relates to the discovery that the dibenzodiazepinone analogues have growth inhibiting activities on tumorigenic cells that are driven by expression of RAS or mutated RAS. Thus the invention includes methods for inhibiting the activity of RAS using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer cell using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer using dibenzodiazepinone analogues; and methods for treating a subject having a RAS driven cancer using dibenzodiazepinone analogues.